✦ LIBER ✦

Clinical trial of an anti-tussive agent

✍ Scribed by S.J. MacHale; V.H. Springett

Book ID: 114092231
Publisher: Elsevier Science
Year: 1962
Tongue: English
Weight: 269 KB
Volume: 43
Category: Article
ISSN: 0041-3879
DOI: 10.1016/s0041-3879(62)80018-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical trials of anti-angiogenic agent

Clinical trials of anti-angiogenic agents

✍ MJ Hawkins 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 119 KB

Clinical trials of anti-amyloid agents

✍ Paul S. Aisen 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 47 KB

An Analysis of Clinical Trials of Mediat

An Analysis of Clinical Trials of Mediator-Specific Anti-Inflammatory Agents

✍ Jonathan E. Sevransky; Charles Natanson 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 120 KB

An inexpensive system for evaluating the

An inexpensive system for evaluating the tussive and anti-tussive properties of chemicals in conscious, unrestrained guinea pigs

✍ J.R. Daller; J. Wong; B.D. Brooks; J.S. McKee 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 684 KB

Anti-angiogenic agents: clinical trial d

Anti-angiogenic agents: clinical trial design and therapies in development

✍ G. Deplanque; A.L. Harris 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Merbarone: an antitumor agent entering c

Merbarone: an antitumor agent entering clinical trials

✍ Alice Glover; Hoo G. Chun; Larry M. Kleinman; David A. Cooney; Jacqueline Plowma 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 454 KB

Merbarone was developed to clinical trial stage on the basis of its 'curative' activity against P388 and L1210 leukemias and moderate activity against B16 melanoma and M5076 sarcoma. Its activity appears to be schedule-dependent favoring a longer duration of administration. The mechanism of action o